These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6252656)

  • 21. Cedivac-FMD can be used according to a marker vaccine principle.
    Chénard G; Selman P; Dekker A
    Vet Microbiol; 2008 Apr; 128(1-2):65-71. PubMed ID: 18035508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of BHK suspension cells for the commercial production of foot and mouth disease vaccines over a twenty year period.
    Radlett PJ; Pay TW; Garland AJ
    Dev Biol Stand; 1985; 60():163-70. PubMed ID: 2995169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mechanisms involved in the prolonged humoral immune response: behavior of aphthous fever virus].
    Wigdorovitz A; Sadir A
    Rev Argent Microbiol; 1996; 28(1):45-54. PubMed ID: 8815460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate.
    Mason PW; Piccone ME; Mckenna TS; Chinsangaram J; Grubman MJ
    Virology; 1997 Jan; 227(1):96-102. PubMed ID: 9007062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis of persistent aphthovirus infection and its differentiation from vaccination response in cattle by use of enzyme-linked immunoelectrotransfer blot analysis with bioengineered nonstructural viral antigens.
    Bergmann IE; de Mello PA; Neitzert E; Beck E; Gomes I
    Am J Vet Res; 1993 Jun; 54(6):825-31. PubMed ID: 8391765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Typing foot-and-mouth disease virus by fluorescent antibody technique.
    Sugimura T; Eissner G
    Natl Inst Anim Health Q (Tokyo); 1976; 16(4):152-9. PubMed ID: 189221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The biological relevance of virus neutralisation sites for virulence and vaccine protection in the guinea pig model of foot-and-mouth disease.
    Dunn CS; Samuel AR; Pullen LA; Anderson J
    Virology; 1998 Jul; 247(1):51-61. PubMed ID: 9683571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards the development of a new foot and mouth disease vaccine.
    Winther MD
    Dev Biol Stand; 1985; 59():73-7. PubMed ID: 2989048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of immune responses after intra-typic heterologous and homologous vaccination against foot-and-mouth disease virus infection in pigs.
    Eblé PL; de Bruin MG; Bouma A; van Hemert-Kluitenberg F; Dekker A
    Vaccine; 2006 Feb; 24(9):1274-81. PubMed ID: 16289709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenging settled opinions in classic foot-and-mouth disease vaccine preparation.
    Barteling SJ; Anemaet DA
    Dev Biol Stand; 1987; 66():531-8. PubMed ID: 3034709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The production of foot-and-mouth disease virus from BHK 21 C 13 cells grown on the surface of glass spheres.
    Spier RE; Whiteside JP
    Biotechnol Bioeng; 1976 May; 18(5):649-57. PubMed ID: 179634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Foot and mouth disease virus vaccines.
    Rodriguez LL; Grubman MJ
    Vaccine; 2009 Nov; 27 Suppl 4():D90-4. PubMed ID: 19837296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The production of foot-and-mouth disease virus from BHK 21 C 13 cells grown on the surface of DEAE sephadex A50 beads.
    Spier RE; Whiteside JP
    Biotechnol Bioeng; 1976 May; 18(5):659-67. PubMed ID: 179635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of three 'ready to formulate' oil adjuvants for foot-and-mouth disease vaccine production.
    Iyer AV; Ghosh S; Singh SN; Deshmukh RA
    Vaccine; 2000 Dec; 19(9-10):1097-105. PubMed ID: 11137244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selection of foot and mouth disease vaccine strains--a review.
    Paton DJ; Valarcher JF; Bergmann I; Matlho OG; Zakharov VM; Palma EL; Thomson GR
    Rev Sci Tech; 2005 Dec; 24(3):981-93. PubMed ID: 16642769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotypic features of BHK-21 cells used for production of foot-and-mouth disease vaccine.
    Amadori M; Volpe G; Defilippi P; Berneri C
    Biologicals; 1997 Mar; 25(1):65-73. PubMed ID: 9167010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development of a method for the quantitative determination of the immunizing antigen (140S) of the foot-and-mouth disease virus].
    Tekerlekov P; Vasileva L; Nikolova E; Veleva E
    Vet Med Nauki; 1985; 22(9):10-9. PubMed ID: 3002008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overview of the inactivation of FMDV and the implications when residual virus is present in vaccines.
    Brown F
    Dev Biol Stand; 1991; 75():37-41. PubMed ID: 1665462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Foot and mouth disease virus transmission among vaccinated pigs after exposure to virus shedding pigs.
    Orsel K; de Jong MC; Bouma A; Stegeman JA; Dekker A
    Vaccine; 2007 Aug; 25(34):6381-91. PubMed ID: 17658199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Very fast (and safe) inactivation of foot-and-mouth disease virus and enteroviruses by a combination of binary ethyleneimine and formaldehyde.
    Barteling SJ; Cassim NI
    Dev Biol (Basel); 2004; 119():449-55. PubMed ID: 15742659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.